Pharmacovigilance for Tuberculosis Medicines

This WHO document is a practical guide and handbook specifically focused on the pharmacovigilance of medicines used to treat tuberculosis (TB).

Here’s a detailed breakdown of what it covers:

The handbook addresses the unique challenges and critical importance of monitoring drug safety in TB treatment.

Key Topics It Covers:

1. The Critical Need for PV in TB:
   • Long & Complex Regimens: TB treatment can last 6 months to 2 years (especially for drug-resistant TB), increasing the risk of cumulative toxicity and late-onset adverse drug reactions (ADRs).
   • Potent Drug Combinations: Patients take multiple powerful drugs simultaneously, making it difficult to identify the culprit of an ADR and increasing the risk of drug-drug interactions.
   • Vulnerable Populations: TB often affects populations with co-morbidities like HIV/AIDS and malnutrition, which can complicate safety monitoring and increase susceptibility to ADRs.
2. Practical Guidance for National TB Programs (NTPs):
   • The handbook is a “how-to” manual for integrating pharmacovigilance into existing National Tuberculosis Programs.
   • It provides a framework for setting up PV systems at the national, regional, and local clinic levels.
3. Active TB Drug-Safety Monitoring and Management (aDSM):
   • This is a central concept in the document. aDSM is a proactive approach to safety monitoring, especially for new TB drugs and regimens.
   • Unlike passive spontaneous reporting, aDSM involves systematic and active follow-up of a specific cohort of patients to detect, report, and manage ADRs more reliably. This is crucial for understanding the safety profile of new drugs like Bedaquiline and Delamanid.
4. Identification and Management of Common ADRs:
   • It details the common adverse reactions associated with first-line and second-line TB drugs.
   • Examples:
     • Hepatotoxicity (from Isoniazid, Rifampin, Pyrazinamide)
     • Skin reactions
     • Gastrointestinal issues
     • Arthralgia (joint pain)
     • Ototoxicity (hearing damage from Aminoglycosides like Streptomycin)
     • Psychiatric effects (from Cycloserine)
5. Causality Assessment:
   • Provides guidance on how to determine if a suspected adverse reaction is actually linked to the TB medication, which is challenging with multi-drug regimens.
6. Reporting and Data Collection:
   • Includes practical tools, such as forms and checklists, to facilitate the standardized reporting of ADRs from TB clinics to national health authorities and the WHO global database.

Why This Handbook is Important:

• Patient Safety: It aims to improve patient care and treatment outcomes by ensuring that the serious ADRs common in TB therapy are detected early and managed effectively, preventing treatment abandonment.
• Protecting New Treatments: It is essential for safeguarding the effectiveness of new and repurposed TB drugs by rapidly identifying any emerging safety concerns.
• Public Health Goal: By promoting safer treatment, it supports the global fight against TB, including drug-resistant TB, and helps maintain functional treatment programs.

In summary, this WHO handbook is an essential tool for healthcare workers, national TB program managers, and pharmacovigilance professionals. It provides the specific knowledge and practical steps needed to monitor the safety of TB drugs effectively, ensuring that life-saving treatment is also as safe as possible.